SIRT1 and Skeletal muscle atrophy: However, all these findings taken together are only the beginning of a major study necessary to prove the real efficacy of SIRT1 as a new pharmacological target in the prevention of muscle degeneration in DMD patients, but they can still be considered a good starting point.